Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIA632 dose-ranging study in moderate to severe cutaneous lichen planus
2025-522300-25-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in lichen planus (LP) comparing GIA632 with Placebo (2 arms). Primary endpoint: IGA response at Week 16. Planned start Nov 2026; status: authorised.
02
Drugs
GIA632
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on 2025-522300-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522300-25-00.